Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2019; 25(26): 3291-3298
Published online Jul 14, 2019. doi: 10.3748/wjg.v25.i26.3291
Published online Jul 14, 2019. doi: 10.3748/wjg.v25.i26.3291
Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation
Jose Tiago Silva, Rafael San-Juan, Mario Fernández-Ruiz, José María Aguado, Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), School of Medicine, Universidad Complutense, Madrid 28041, Spain
Author contributions: Silva JT was responsible for the literature review and the drafting and writing of the manuscript; San-Juan R, Fernández-Ruiz M and Aguado JM contributed to the editing, critical revision and approval of the final version.
Supported by “ Plan Nacional de I+D+I” ; Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias [FIS] PI14/00174), Subdirección General de Redes y Centros de Investigació n Cooperativa, Spanish Ministry of Science, Innovation and Universities, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016) ; and was cofinanced by the European Development Regional Fund (EDRF) "A way to achieve Europe" .
Conflict-of-interest statement: The authors have no conflicts of interest related to this publication.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jose Tiago Silva, MD, PhD, Attending Doctor, Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), School of Medicine, Universidad Complutense, 2ª planta, bloque D. Avda. de Córdoba, s/n, Madrid 28041, Spain. j.tiago.silva@hotmail.com
Telephone: +34-91-3908000 Fax: +34-91-4695775
Received: February 20, 2019
Peer-review started: February 20, 2019
First decision: April 30, 2019
Revised: May 30, 2019
Accepted: June 7, 2019
Article in press: June 7, 2019
Published online: July 14, 2019
Peer-review started: February 20, 2019
First decision: April 30, 2019
Revised: May 30, 2019
Accepted: June 7, 2019
Article in press: June 7, 2019
Published online: July 14, 2019
Core Tip
Core tip: Active tuberculosis after solid organ transplantation, particularly after liver transplantation, has a dismal outcome. This review focuses on the burden of active tuberculosis after liver transplantation and summarizes the most recent data concerning the use of isoniazid for the treatment of latent tuberculosis infection in liver transplant recipients and candidates. In addition, we review the most relevant clinical experience in the use of fluoroquinolones as an alternative approach with a favorable safety profile for the treatment of latent tuberculosis infection in the liver transplant setting.